Reuters logo
BRIEF-Ampio receives guidance from the FDA
February 27, 2017 / 1:52 PM / 7 months ago

BRIEF-Ampio receives guidance from the FDA

Feb 27 (Reuters) - Ampio Pharmaceuticals Inc:

* Ampio receives guidance from the FDA and proposes a path for approval for single-injection ampion™ for the treatment of pain due to severe osteoarthritis of the knee

* Says ampio has proposed a small pre-approval study, randomized 6 to 1 on patients with severe oak

* Says study will be completed concurrently with preparation for biologicals licensing application (bla) submission

* Says Ampio has requested expedited review/approval for this serious medical condition with an unmet medical need Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below